Conference Coverage

PSYCHIATRY UPDATE 2016


 

Bipolar Depression: Presentation, Diagnosis, and Treatment in the Outpatient Psychiatry Practice Setting
Peter J. Weiden, MD, University of Illinois at Chicago

Bipolar depression can overlap with major depressive disorder (MDD), but treatments for the 2 disorders diverge, Dr. Weiden explained in an industry-sponsored symposium. Adding an antidepressant to a mood stabilizer is no more effective than a mood stabilizer plus placebo for treating bipolar depression. Lurasidone (Latuda) is indicated for treating a depressive episode in a patient with a diagnosis of bipolar I disorder as monotherapy or adjunctive therapy with lithium or valproate. As monotherapy and adjunctive therapy, lurasidone reduced Montgomery-Åsburg Depression Rating Scale scores score over 6 weeks compared with placebo. Nausea and vomiting are most common adverse effects, then akathisia and sedation.

Pages

Recommended Reading

FDA announces new plan to combat opioid abuse
MDedge Psychiatry
NIDA releases strategic plan to prevent, treat substance use disorders
MDedge Psychiatry
ThriveNYC could help treat and destigmatize mental, behavioral disorders
MDedge Psychiatry
Designer drug symptoms can mimic schizophrenia, anxiety, depression
MDedge Psychiatry
Opioid prescribing: An odyssey of challenges
MDedge Psychiatry
Opiate drug detox appears safe in pregnancy
MDedge Psychiatry
Pot tied to increased risk of substance use disorders, not depression or anxiety
MDedge Psychiatry
We are not ‘psychiatrists’; 'The beauty of the asylum’; Challenges with false-positive urine drug screens
MDedge Psychiatry
Marijuana tourists also visiting Colorado EDs
MDedge Psychiatry
VIDEO: How proposed patient substance use privacy rule impacts physicians
MDedge Psychiatry